Analyst Craig Hettenbach of Morgan Stanley maintained a Hold rating on Definitive Healthcare Corp (DH – Research Report), with a price target of $5.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Craig Hettenbach has given his Hold rating due to a combination of factors impacting Definitive Healthcare Corp’s performance. Although the company reported slightly better-than-expected revenue and EBITDA figures for the fourth quarter, these positive results were overshadowed by significant challenges. The company experienced increased customer churn and a decline in total customer count, which negatively affected its operational performance.
Moreover, the guidance for 2025 indicates a decline in both revenue and EBITDA compared to market expectations, with anticipated negative operating leverage impacting margins. The new CEO, Kevin Coop, acknowledged the need for further improvements in the company’s market strategy and product value capture. Given these mixed signals and ongoing challenges, Hettenbach’s Hold rating reflects a cautious outlook on the company’s near-term prospects.